Private company

La Jolla Pharmaceutical Company

American biological products company based in San Diego, founded in 1989.¹

Last updated Oct 18, 2026.

Overview

1989Founded¹

IndustryBiological Products, (No Diagnostic Substances)¹
HeadquartersSan Diego¹
Websitelajollapharmaceutical.com
Incorporated inDE³
Business address201 Jones Road, Suite 400, Waltham, Ma 02451³
Filer categoryNon-accelerated filer, Smaller reporting company³

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

28.8%Operating margin⁴

26.0%Net margin⁴

126.6%Revenue growth, 2021⁴

$28.2MFree cash flow⁴

Where the money goes

Where each dollar of revenue went, fiscal 2021

Selling, general and adminOther costsProfit

Research and development7¢$5.0M
Selling, general and admin47¢$35.4M
Other costs21¢$15.6M
Income tax0¢$49.0K
Profit26¢$19.7M

Out of $75.7M in revenue.⁴

Where each dollar of operating cash went, fiscal 2021

Share buybacksKept or used elsewhere

Capital spending0¢$9.0K
Share buybacks12¢$3.4M
Kept or used elsewhere88¢$24.9M

Out of $28.2M of cash from operations.⁴

Financial statements

Revenue⁵⁶⁷⁸⁴$75.7M in 2021+7064% since 2015

Operating income⁵⁶⁷⁸⁴$21.8M in 2021

Net income⁵⁶⁷⁸⁴$19.7M in 2021

Fiscal year	2015	2016	2017	2018	2019	2020	2021
Revenue	$1.1M⁵	$616.0K⁶	$0⁶	$10.1M⁷	$23.1M⁸	$33.4M⁴	$75.7M⁴
Cost of revenue		$0⁶	$0⁶	$1.1M⁷	$2.4M⁸	$7.8M⁸
Research and development	$29.1M⁵	$62.3M⁶	$84.6M⁶	$43.3M⁷	$85.3M⁸	$23.0M⁴	$5.0M⁴
Selling, general and admin		$16.7M⁶	$30.9M⁶	$23.6M⁷	$45.1M⁸	$38.4M⁴	$35.4M⁴
Operating income	-$42.0M⁵	-$78.4M⁶	-$115.4M⁶	-$57.9M⁷	-$109.8M⁸	-$35.8M⁴	$21.8M⁴
Interest		$0⁶	$0⁶	$7.3M⁶
Income tax	$0⁵	$0⁶	$0⁶	$0¹¹	$0¹¹	$0⁴	$49.0K⁴
Net income	-$41.9M⁵	-$78.2M⁶	-$114.8M⁶	-$62.1M⁷	-$116.5M⁸	-$39.4M⁴	$19.7M⁴
Earnings per share						-$1.44⁴	$0.72⁴
Earnings per share (diluted)						-$1.44⁴	$0.58⁴

Total assets¹²⁵⁶¹¹⁸⁴$101.2M in 2021−22% since 2015

Total liabilities⁵⁶¹¹⁸⁴$168.0M in 2021+1621% since 2016

Shareholders’ equity⁶¹¹⁸⁴-$66.7M in 2021

Cash⁵⁶¹¹⁸⁴$46.7M in 2021−63% since 2015

Long-term debt⁶$124.3M in 2018

Fiscal year	2015	2016	2017	2018	2019	2020	2021
Cash	$126.5M⁵	$65.7M⁶	$90.9M⁶	$172.6M¹¹	$87.8M⁸	$21.2M⁴	$46.7M⁴
Current assets	$127.5M¹²	$67.4M⁵	$94.1M⁶	$181.1M¹¹	$97.5M⁸	$36.5M⁴	$67.3M⁴
Total assets	$129.3M¹²	$70.8M⁵	$119.5M⁶	$204.3M¹¹	$132.2M⁸	$72.2M⁴	$101.2M⁴
Current liabilities	$4.8M¹²	$9.8M⁵	$18.6M⁶	$25.9M¹¹	$24.6M⁸	$12.3M⁴	$17.6M⁴
Long-term debt			$0⁶	$124.3M⁶
Total liabilities		$9.8M⁵	$31.3M⁶	$168.4M¹¹	$188.2M⁸	$160.3M⁴	$168.0M⁴
Shareholders’ equity	$124.5M⁶	$61.0M⁶	$88.2M¹¹	$35.9M⁸	-$56.0M⁴	-$88.1M⁴	-$66.7M⁴
Shares outstanding	18.2M shares¹²	18.3M shares⁵	22.2M shares⁶	26.3M shares¹¹	27.2M shares⁸	27.4M shares⁴	26.8M shares⁴

Cash from operations⁵⁶¹¹⁸⁴$28.2M in 2021

Capital spending⁵⁶¹¹⁸⁴$9.0K in 2021−100% since 2015

Free cash flow⁵⁶¹¹⁸⁴$28.2M in 2021

Fiscal year	2015	2016	2017	2018	2019	2020	2021
Cash from operations	-$25.2M⁵	-$58.7M⁶	-$85.1M⁶	-$152.4M¹¹	-$85.0M⁸	-$37.6M⁴	$28.2M⁴
Capital spending	$1.8M⁵	$2.2M⁶	$9.2M⁶	$2.3M¹¹	$698.0K⁸		$9.0K⁴
Free cash flow	-$27.0M	-$60.9M	-$94.3M	-$154.7M	-$85.6M		$28.2M
Share buybacks							$3.4M⁴

Compare La Jolla Pharmaceutical Company with another company

Leadership

Who has led La Jolla Pharmaceutical Company, and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

Steven B. Engle2006

President

Chief financial officer

Chief operating officer

Jennifer Carver2017–2019

19901995200020052010201520202025

Chief executive officerGeorge F. Tidmarsh Jan 31, 2012 to Apr 17, 2019¹³
Chief executive officerSteven B. Engle Feb 10, 2006 to Feb 10, 2006¹⁴
Chief executive officerDeirdre Gillespie Mar 16, 2006 to May 18, 2011¹⁵
ChairSteven B. Engle Feb 10, 2006 to Feb 10, 2006¹⁴
PresidentGeorge F. Tidmarsh Jan 31, 2012 to Apr 17, 2019¹³
PresidentDeirdre Gillespie Feb 7, 2007 to May 18, 2011¹⁶
Chief financial officerMichael S. Hearne Jun 3, 2020 to Aug 24, 2022¹⁷
Chief financial officerKevin C. Tang Jun 4, 2020 to Aug 24, 2022¹⁸
Chief financial officerDennis Mulroy Apr 8, 2015 to Jun 2, 2020¹⁹
Chief financial officerGail A. Sloan May 28, 2010 to Apr 21, 2011²⁰
Chief financial officerNiv Edward Caviar May 10, 2007 to Feb 3, 2009²¹
Chief operating officerJennifer Carver Jan 6, 2017 to Mar 4, 2019²²

Board members and other officers (29)

OfficerMichael S. Hearne Jun 4, 2020 to Aug 24, 2022¹⁸
Chief Commercial OfficerDarryl Wellinghoff Mar 13, 2019 to Apr 17, 2020²³
Chief Scientific OfficerJames Rolke Jan 6, 2017 to Jun 2, 2020²⁴
Sr. Vice President, OperationsJennifer Carver Jan 11, 2016 to Jan 11, 2016²⁵
Chief Medical OfficerLakhmir S. Chawla Jul 8, 2015 to Sep 17, 2020²⁶
Vice President ManufacturingLuke Seikkula Mar 2, 2007 to Feb 3, 2009²⁷
Sen Dir Investor RelationsAndrew Wiseman Feb 10, 2006 to Feb 7, 2007²⁸
VP of ManufacturingBruce K. Bennett Jr. Feb 10, 2006 to Apr 18, 2006²⁹
VP of FinanceGail A. Sloan Feb 10, 2006 to Jan 4, 2010³⁰
Vice President Quality SystemJosefina T. Elchico Feb 10, 2006 to Mar 5, 2009³¹
CSO & Exec VP of ResearchMatthew D. Linnik Feb 10, 2006 to Dec 27, 2006³²
VP of Product DevelopmentPaul Jenn Feb 10, 2006 to Jan 11, 2007³³
VP of Human ResourcesTeddi Reilly Feb 10, 2006 to Apr 18, 2006³⁴
Sr Dir Regulatory AffairsLisa I. Koch May 22, 2006 to Feb 7, 2007³⁵
Chief Medical OfficerMichael James Byron Tansey Jul 18, 2006 to Feb 3, 2009³⁶
Board memberDavid A. Ramsay Oct 18, 2019 to Aug 24, 2022³⁷
Board memberKevin C. Tang Sep 26, 2014 to Aug 24, 2022³⁸
Board memberCraig A. Johnson Oct 17, 2013 to Aug 24, 2022³⁹
Board memberLaura L. Douglass Oct 17, 2013 to Aug 24, 2022⁴⁰
Board memberSaiid Zarrabian Jan 30, 2012 to May 15, 2015⁴¹
Board memberGeorge F. Tidmarsh Jan 31, 2012 to Apr 17, 2019¹³
Board memberBertrand C. Liang Dec 8, 2010 to Dec 8, 2010⁴²
Board memberCraig R. Smith Feb 10, 2006 to Feb 27, 2009⁴³
Board memberRobert Fildes Phd. Feb 10, 2006 to Jun 2, 2010⁴⁴
Board memberJames N. Topper Feb 14, 2006 to Feb 26, 2009⁴⁵
Board memberNader J. Naini Feb 14, 2006 to May 24, 2007⁴⁶
Board memberDeirdre Gillespie Mar 16, 2006 to May 18, 2011¹⁵
Board memberFrank Young May 22, 2006 to May 23, 2008⁴⁷
Board memberMartin P. Sutter May 22, 2006 to Aug 7, 2009⁴⁸

Timeline

Jan 31, 2012New chief executive George F. Tidmarsh becomes CEO¹³
Mar 16, 2006New chief executive Deirdre Gillespie becomes CEO¹⁵
Feb 10, 2006New chief executive Steven B. Engle becomes CEO¹⁴
1989Founded Founded¹

Filings

86 filings to the SEC since October 2021: 2 annual reports, 3 quarterly reports, 5 major events, 53 insider forms, 7 large holders, 16 other. The latest 20:

Feb 14, 2023SC 13G/A LA JOLLA PHARMACEUTICAL COMPANY EDGAR
Sep 1, 202215-12G FORM 15 EDGAR
Aug 29, 2022SC 13D/A EDGAR
Aug 29, 2022SC 13D EDGAR
Aug 24, 2022SC 13D/A AMENDMENT NO. 19 EDGAR
Aug 24, 20224 FORM 4 SUBMISSION EDGAR
Aug 24, 20224 FORM 4 SUBMISSION EDGAR
Aug 24, 20224 FORM 4 SUBMISSION EDGAR
Aug 24, 20224 FORM 4 SUBMISSION EDGAR
Aug 24, 20224 FORM 4 SUBMISSION EDGAR
Aug 24, 20224 FORM 4 SUBMISSION EDGAR
Aug 24, 20224 FORM 4 SUBMISSION EDGAR
Aug 24, 20224 FORM 4 SUBMISSION EDGAR
Aug 24, 20224 FORM 4 SUBMISSION EDGAR
Aug 23, 2022S-8 POS S-8 POS 333-227819 EDGAR
Aug 23, 2022S-8 POS S-8 POS 333-214722 EDGAR
Aug 23, 2022S-8 POS S-8 POS 333-207212 EDGAR
Aug 23, 2022S-8 POS S-8 POS 333-221197 EDGAR
Aug 23, 2022S-8 POS S-8 POS 333-193016 EDGAR
Aug 22, 202225-NSE EDGAR

The 86 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 7 such filings since October 2021:

Feb 14, 2023SC 13G/A
Aug 29, 2022SC 13D/A
Aug 29, 2022SC 13D
Aug 24, 2022SC 13D/A
Jul 12, 2022SC 13D/A
Feb 14, 2022SC 13G/A
Dec 2, 2021SC 13D/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
WikidataLa Jolla Pharmaceutical Company on Wikidata
2
SEC EDGARLa Jolla Pharmaceutical Company filings on SEC EDGAR
3
SEC EDGARLa Jolla Pharmaceutical Company filings on SEC EDGAR
4
SEC EDGARLa Jolla Pharmaceutical Company 10-K for fiscal 2021
5
SEC EDGARLa Jolla Pharmaceutical Company 10-K for fiscal 2015
6
SEC EDGARLa Jolla Pharmaceutical Company 10-K for fiscal 2016
7
SEC EDGARLa Jolla Pharmaceutical Company 10-K for fiscal 2018
8
SEC EDGARLa Jolla Pharmaceutical Company 10-K for fiscal 2019
9
SEC EDGARLa Jolla Pharmaceutical Company 10-Q for fiscal 2022
10
SEC EDGARLa Jolla Pharmaceutical Company 10-Q for fiscal 2022
11
SEC EDGARLa Jolla Pharmaceutical Company 10-K for fiscal 2018
12
SEC EDGARLa Jolla Pharmaceutical Company 10-K for fiscal 2015
13
SEC EDGARGeorge F. Tidmarsh, Chief executive officer
14
SEC EDGARSteven B. Engle, Chief executive officer
15
SEC EDGARDeirdre Gillespie, Chief executive officer
16
SEC EDGARDeirdre Gillespie, President
17
SEC EDGARMichael S. Hearne, Chief financial officer
18
SEC EDGARKevin C. Tang, Chief financial officer
19
SEC EDGARDennis Mulroy, Chief financial officer
20
SEC EDGARGail A. Sloan, Chief financial officer
21
SEC EDGARNiv Edward Caviar, Chief financial officer
22
SEC EDGARJennifer Carver, Chief operating officer
23
SEC EDGARDarryl Wellinghoff, Chief Commercial Officer
24
SEC EDGARJames Rolke, Chief Scientific Officer
25
SEC EDGARJennifer Carver, Sr. Vice President, Operations
26
SEC EDGARLakhmir S. Chawla, Chief Medical Officer
27
SEC EDGARLuke Seikkula, Vice President Manufacturing
28
SEC EDGARAndrew Wiseman, Sen Dir Investor Relations
29
SEC EDGARBruce K. Bennett Jr., VP of Manufacturing
30
SEC EDGARGail A. Sloan, VP of Finance
31
SEC EDGARJosefina T. Elchico, Vice President Quality System
32
SEC EDGARMatthew D. Linnik, CSO & Exec VP of Research
33
SEC EDGARPaul Jenn, VP of Product Development
34
SEC EDGARTeddi Reilly, VP of Human Resources
35
SEC EDGARLisa I. Koch, Sr Dir Regulatory Affairs
36
SEC EDGARMichael James Byron Tansey, Chief Medical Officer
37
SEC EDGARDavid A. Ramsay, Board member
38
SEC EDGARKevin C. Tang, Board member
39
SEC EDGARCraig A. Johnson, Board member
40
SEC EDGARLaura L. Douglass, Board member
41
SEC EDGARSaiid Zarrabian, Board member
42
SEC EDGARBertrand C. Liang, Board member
43
SEC EDGARCraig R. Smith, Board member
44
SEC EDGARRobert Fildes Phd., Board member
45
SEC EDGARJames N. Topper, Board member
46
SEC EDGARNader J. Naini, Board member
47
SEC EDGARFrank Young, Board member
48
SEC EDGARMartin P. Sutter, Board member